Biogen

Welcome to the 'Biogen' tag page at Technorati. This page features content from the farthest reaches of the Blogosphere that authors have "tagged" with 'Biogen'.

Latest blogosphere posts tagged “Biogen”

• Mullen to Relinquish Biogen Idec Reins, Joule to Test Ethanol Tech, Dicerna to Team with Kyowa Hakko Kirin, & More Boston-Area Life Sciences News

  
  Xconomy — Authority: 647
  Roundup , Life Sciences , people Rebecca Zacks wrote: I’ve got a couple weeks’ worth of New England life sciences news to catch you up on, so let’s dive in. —Shares of Watertown, MA-based pSivida (NASDAQ: PSDV ) jumped more than 50 percent after the company reported its treatment for diabetic ...
  13 hours ago

• Investors Cheer Departure of Biogen Chief

  
  DealBook — Authority: 754
  Investors welcomed the upcoming departure of Biogen Idec s chief executive, James Mullen, sending the companys shares higher in early trading on Tuesday.
  15 hours ago

• Pharmalot… Pharmalittle… Good Morning

  
  Pharmalot — Authority: 539
  Top of the morning to you. Hope your adjustment to the usual work routine went well yesterday. As always, there is much to do. First up on our agenda - shepharding one of the short people to the local schoolhouse. So while we prepare for the challenge, here are a few items to help you with your own challenges. ...
  1 day ago

• Biogen Chief and Icahn Adversary to Retire

  
  DealBook — Authority: 754
  Carl C. Icahn may have been pleased to learn that one of his adversaries, James C. Mullen, the chief executive of Biogen Idec, is retiring as president and chief executive of the firm as of June 8.
  1 day ago

• Chief of Struggling Biotech Company, Biogen Idec, to Retire

  
  NYT > Theater — Authority: 901
  The company is trying to overcome concerns about the safety of its most important drug, Tysabri.
  1 day ago

• Biogen Idec CEO Jim Mullen Stepping Down, After Tumultuous Year of Shareholder Activism

  
  Xconomy — Authority: 647
  Biotech , people , Multiple Sclerosis Luke Timmerman wrote: [ Updated 6:05 pm Eastern 1/4/10 ] Biogen Idec, the world’s largest maker of multiple sclerosis drugs and an anchor of Boston’s biotech cluster, is looking for a new CEO. The Cambridge, MA-based company (NASDAQ: BIIB ) said today that ...
  2 days ago

• The Boston Deals You Missed During the Holidays: Cash for Kala Pharma, Funds for ViewFinity, Silver for SCVNGR, & More

  
  Xconomy — Authority: 647
  Roundup , deals , VC Ryan McBride wrote: Feeling a bit out of the loop on the New England tech and life sciences news? Don’t fret. We’ve compiled the Boston-area deals you may have missed during the last couple of weeks of 2009. There were enough of them to indicate that tech lawyers and execs were ...
  2 days ago

• Top Picks for 2010: ImmunoGen (IMGN)

  
  BloggingStocks — Authority: 653
  Filed under: Newsletters , Stocks to Buy , best stocks for 2010 This post is part of a special report, Top Picks for 2010, the 27th annual survey in which TheStockAdvisors.com asks the nations leading advisors for their single favorite stock for the new year. See all 80 stocks listed here . "Our ...
  1 week ago

• Ambit Signs Big Deal With Astellas, Xenomics Alleges Fraud at Sequenom, Arena Seeks FDA Approval for Weight-Loss Drug & More San Diego Life Sciences News

  
  Xconomy — Authority: 647
  Roundup , Life Sciences , deals Bruce V. Bigelow wrote: Despite the fact that there are no snow days in San Diego, we still saw occasional flurries—of life sciences news—in the days before Christmas. Here at Xconomy, we’re wishing everyone happy holidays and an exponential New Year. — Scott ...
  1 week ago

• Biogen Drops Facet Bid, Aveo Reveals IPO Ambitions, Pfizer Partners with Adimab, & More Boston-Area Life Sciences News

  
  Xconomy — Authority: 647
  Roundup , Life Sciences , acquisitions Rebecca Zacks wrote: New England’s drug developers and device makers are squeezing in a few more partnerships, acquisitions, financings, and strategic moves before the year’s end. —Acceleron Pharma, the Cambridge, MA-based biotech that’s building its own ...
  2 weeks ago

• Closing Bell: Decoupling of inverse dollar and stock relationship (POT, CHTT, ETFC, ATHX, V, BIIB)

  
  BloggingStocks — Authority: 653
  Filed under: Potash Corp. of Saskatchewan (POT) , E*TRADE (ETFC) , Visa Inc. (V) Stocks had effectively no real market moving economic data to trade off of. We also saw a break-away from the inverse relationship between stocks and the US Dollar, as both were up on the day. Here were todays unofficial closing ...
  2 weeks ago

• Impactiviti Daily 121809

  
  Impactiviti blog — Authority: 119
  This will be the final Impactiviti Daily for 2009. We’ll pick up again in the new year. Have a delightful holiday season! TODAY’S NEWS Deals – J&J and Merck get hits, Biogen strikes out . From PharmaExec – a new commercialization model needed for pharma? – The days when ...
  2 weeks ago

• Hedge Funds Help Scuttle Biogens Facet Bid

  
  DealBook — Authority: 754
  Two hedge funds helped Facet Biotech fend off a $420 million unsolicited bid from Biogen Idec.
  2 weeks ago

• Biogen Idec Bid for Facet Biotech Shot Down, But the Show’s Not Over

  
  Xconomy — Authority: 647
  Biotech , deals , Finances Luke Timmerman wrote: Biogen Idec failed to persuade shareholders to approve its $450 million hostile takeover bid for Redwood City, CA-based Facet Biotech, but a statement today suggests that this particular corporate dance isn’t over yet. Shareholders of Facet ...
  2 weeks ago

• Aveo Pharmaceuticals Eyes $86.3M IPO

  
  Xconomy — Authority: 647
  Life Sciences , IPO , Kidney Cancer Ryan McBride wrote: Aveo Pharmaceuticals indicated late yesterday that it wants to take the plunge into the public markets, filing papers with the SEC to raise up to $86.25 million in an initial public offering. It’s a brave move, considering that public markets ...
  2 weeks ago

• Biogen Idec Board in Flux, Cubist Acquires Calixa, ImmunoGen Drug Passes Clinical Test, & More Boston-Area Life Sciences News

  
  Xconomy — Authority: 647
  Roundup , Life Sciences , startups Rebecca Zacks wrote: Gadzooks, was this a busy news week for the biotech, devices, and healthcare IT sectors in New England. Here’s the lightning round version: —Luke examined Cambridge, MA-based Biogen Idec (NASDAQ: BIIB )’s e fforts to create antibody drugs that ...
  3 weeks ago

• Pharmalot… Pharmalittle… Good Morning

  
  Pharmalot — Authority: 539
  Rise and shine, everyone, another day has begun. And as the Morning Mayor used to say, every brand new day should be unwrapped like a precious gift. As you can tell, we like comforting thoughts. So as you unwrap your proverbial ribbon, we have assembled a few items to help you along. Whatever you do today, we hope you ...
  3 weeks ago

• Biogen Prepared for Proxy Battle for Facet Biotech

  
  Xconomy — Authority: 647
  Proxy Battle , Life Sciences , Multiple Sclerosis Ryan McBride wrote: Cambridge, MA-based Biogen Idec told investors today that it’s willing to wage a proxy battle to take control of the board of Facet Biotech, which it has been trying to acquire without success since September. Biogen (NASDAQ: ...
  3 weeks ago

• New Faces, New Vacancies on Biogen Idec Board May Foretell Another Proxy Battle

  
  Xconomy — Authority: 647
  Biotech , people , Drugs Luke Timmerman wrote: The Biogen Idec boardroom has seen a lot of turnover in the past few months, and who ends up filling the empty slots could say a lot about whether the Cambridge, MA-based biotech company (NASDAQ: BIIB ) will have another proxy fight with billionaire ...
  3 weeks ago

• (BIIB) Biogen’s Rheumatoid Arthritis Candidate Effective

  
  Stock Blog Hub — Authority: 469
  Biogen Idec ( BIIB ) and Genentech Inc., a wholly owned member of the Roche Group ( RHHBY ), recently reported positive phase III results on their rheumatoid arthritis (RA) candidate, ocrelizumab. Results from the study (STAGE) showed that the humanized anti-CD20 monoclonal antibody, when given in combination with ...
  3 weeks ago

Comments about Biogen